Defining the role of BTG1 mutation in driving a new form of therapy-resistant DLBCLs.AMAri M. MelnickLeukemia & Lymphoma Society · 2018–2020LLS 3384-19
Exploring the roles of EZH2 mutation for the development of double hit lymphoma and acquisition of chemotherapy resistanceAMAri M. MelnickLeukemia & Lymphoma Society · 2023–2024LLS 3426-24
Define genetically/epigenetically modified targets in the immune niche of DLBCLs- Project 2AMAri M. MelnickDBDarko BarisicMPILeukemia & Lymphoma Society · 2022–2027 · via University Health NetworkUHN 224060-04Ending soon
Dual Targeting of Toll-like and Nod-like Receptors in Tumor ImmunotherapyJMJulie Magarian BlanderLeukemia & Lymphoma Society · 2016–2019LLS 1328-15
Project 1: Translational Discovery in Peripheral T-Cell LymphomasGGGiorgio Ga. InghiramiLeukemia & Lymphoma Society · 2015–2020 · via Dana-Farber Cancer Institute7011-16 PROJECT 1
Core C: Translational Discovery in Peripheral T-Cell LymphomasGGGiorgio Ga. InghiramiLeukemia & Lymphoma Society · 2015–2020 · via Dana-Farber Cancer Institute7011-16 CORE C
Translational Discovery in Peripheral T-Cell LymphomasGGGiorgio Ga. InghiramiLeukemia & Lymphoma Society · 2022–2026 · via Memorial Sloan Kettering Cancer CenterLLS SCOR -7026-21Ending soon
Chromatic Mechanisms and Epigenetic Targeting in Hematological MalignanciesOEOlivier ElementoLeukemia & Lymphoma Society · 2012–2018 · via University of Florida7006-13
Restoring lymphoma immunosurveillance by combined EZH2 inhibition and immunotherapy.RZRoberta ZappasodiLeukemia & Lymphoma Society · 2021–2025LLS 6643-22Recently ended
Targeting oncogenic translation in B-cell lymphomasZCZhengming ChenLeukemia & Lymphoma Society · 2018–2020LLS-TRP-R6510-19
Longitudinal functional genomics in mantle cell lymphoma therapy and drug resistanceSCSelina Chen-KiangGGGiorgio Ga. InghiramiJPJihye PaikOEOlivier Elemento+4 moreMPILeukemia & Lymphoma Society · 2018–2023LLS 180078-01
Project 6: Clinical Epigenetics in Hematological MalignanciesAMAri M. MelnickMLMeng LiLeukemia & Lymphoma Society · 2015–2018 · via University of Florida7006-13
Core C: Consortium For The Study of Chromatin Biology And Epigenetic Training In Hematological MalignanciesAMAri M. MelnickCMCem MeydanLeukemia & Lymphoma Society · 2015–2018 · via University of Florida7006-13
Precision medicine deployment of mechanism based Epigenetic – Immune therapy for B-cell lymphomaAMAri M. MelnickZCZhengming ChenLeukemia & Lymphoma Society · 2018–2021LLS-TRP-6572-19
Therapeutic Implications of Altered Epigenetics and DNA Damage Responses in Hematologic DisordersAMAri M. MelnickCMCem MeydanLeukemia & Lymphoma Society · 2016–2022 · via University Health NetworkUHN LLS 9238-16
The Role of SPEN as Tumor Suppressor in BN2 DLBCLAMAri M. MelnickLeukemia & Lymphoma Society · 2022–2025LLS 8031-23Recently ended
Algorithmically-Driven Personalized Combination Therapy for CLLDADan Avi LandauNONathaniel OmansLeukemia & Lymphoma Society · 2016–2020LLS 6523-17
Developing Novel Therapeutic Approaches for Classical and Variant Hairy Cell Leukemia (Project 1)DADan Avi LandauLeukemia & Lymphoma Society · 2021–2025 · via Memorial Sloan Kettering Cancer CenterHCL8028-22Recently ended
Defining the role of DNA methylation modifier mutations in reshaping blood differentiation topologyDADan Avi LandauLeukemia & Lymphoma Society · 2021–2026LSS 1373-21Ending soon
Advancing the therapeutic landscape for Chronic Myelomonocytic Leukemia (CMML)DADan Avi LandauSYSangho YoonLeukemia & Lymphoma Society · 2023–2027 · via H. Lee Moffitt Cancer Center & Research InstituteMCCRI 69-22751-01-01-G4Ending soon